A new study highlights that skin pigmentation can influence how quickly medications reach their intended targets, with melanin potentially binding to certain drugs and slowing their efficacy. Researchers argue that this overlooked factor in drug testing could lead to varied drug responses across skin tones, impacting drug safety and dosing. Current FDA guidelines lack provisions addressing pigmentation’s effects on drug interactions, raising concerns for inclusivity in treatment efficacy.
